RUBY Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-02-24 | Appelhans Dannielle | officer: CEO and President | 0 | S-Sale | D | 10,385 | 0.13 | 1,323.05 |
| 2023-02-01 | Appelhans Dannielle | officer: CEO and President | 10,385 | S-Sale | D | 3,878 | 0.25 | 969.50 |
| 2023-02-01 | CAGNONI PABLO J | director | 66,082 | S-Sale | D | 8,448 | 0.25 | 2,112.00 |
| 2023-01-31 | Appelhans Dannielle | officer: CEO and President | 22,500 | M-Exempt | D | 7,500 | 0.00 | 0.00 |
| 2023-01-31 | Appelhans Dannielle | officer: CEO and President | 14,263 | M-Exempt | A | 7,500 | 0.00 | 0.00 |
| 2023-01-31 | Turka Laurence A. | officer: Chief Scientific Officer | 25,875 | M-Exempt | D | 8,625 | 0.00 | 0.00 |
| 2023-01-31 | Turka Laurence A. | officer: Chief Scientific Officer | 18,391 | S-Sale | D | 2,593 | 0.24 | 622.32 |
| 2023-01-31 | Turka Laurence A. | officer: Chief Scientific Officer | 20,984 | M-Exempt | A | 8,625 | 0.00 | 0.00 |
| 2023-01-31 | CAGNONI PABLO J | director | 75,000 | M-Exempt | D | 25,000 | 0.00 | 0.00 |
| 2023-01-31 | CAGNONI PABLO J | director | 74,530 | S-Sale | D | 7,240 | 0.24 | 1,744.84 |
| 2023-01-31 | CAGNONI PABLO J | director | 81,770 | M-Exempt | A | 25,000 | 0.00 | 0.00 |
| 2023-01-29 | Turka Laurence A. | officer: Chief Scientific Officer | 14,874 | M-Exempt | D | 7,438 | 0.00 | 0.00 |
| 2023-01-29 | Turka Laurence A. | officer: Chief Scientific Officer | 12,359 | M-Exempt | A | 7,438 | 0.00 | 0.00 |
| 2023-01-29 | CAGNONI PABLO J | director | 42,500 | M-Exempt | D | 21,250 | 0.00 | 0.00 |
| 2023-01-29 | CAGNONI PABLO J | director | 56,770 | M-Exempt | A | 21,250 | 0.00 | 0.00 |
| 2022-08-10 | Appelhans Dannielle | officer: Chief Operating Officer | 37,500 | M-Exempt | D | 12,500 | 0.00 | 0.00 |
| 2022-08-10 | Appelhans Dannielle | officer: Chief Operating Officer | 6,763 | S-Sale | D | 5,737 | 0.80 | 4,589.60 |
| 2022-08-09 | Appelhans Dannielle | officer: Chief Operating Officer | 12,500 | M-Exempt | A | 12,500 | 0.00 | 0.00 |
| 2022-07-29 | Schaffert Susanne | director | 50,000 | A-Award | A | 50,000 | 0.70 | 35,100.00 |
| 2022-05-12 | Holles Natalie C. | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Prener Anne | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Symonds Jonathan | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | AFEYAN NOUBAR | director, 10 percent owner | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Sohn Catherine A. | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Rosenblatt Michael | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Cuss Francis M | director | 25,000 | A-Award | A | 25,000 | 1.24 | 31,000.00 |
| 2022-05-12 | Epstein David R | director | 499,762 | A-Award | A | 499,762 | 1.24 | 619,704.88 |
| 2022-04-21 | Epstein David R | director | 4,720,012 | P-Purchase | A | 30,000 | 1.44 | 43,329.00 |
| 2022-02-01 | CAGNONI PABLO J | director, officer: CEO and President | 100,000 | A-Award | D | 100,000 | 0.00 | 0.00 |
| 2022-02-01 | CAGNONI PABLO J | director, officer: CEO and President | 365,000 | A-Award | D | 365,000 | 6.75 | 2,463,750.00 |
| 2022-02-01 | CAGNONI PABLO J | director, officer: CEO and President | 63,750 | M-Exempt | D | 21,250 | 0.00 | 0.00 |
| 2022-02-01 | CAGNONI PABLO J | director, officer: CEO and President | 35,520 | S-Sale | D | 6,730 | 6.57 | 44,236.29 |
| 2022-02-01 | Turka Laurence A. | officer: Chief Scientific Officer | 34,500 | A-Award | D | 34,500 | 0.00 | 0.00 |
| 2022-02-01 | Turka Laurence A. | officer: Chief Scientific Officer | 143,750 | A-Award | D | 143,750 | 6.75 | 970,312.50 |
| 2022-02-01 | Turka Laurence A. | officer: Chief Scientific Officer | 22,312 | M-Exempt | D | 7,438 | 0.00 | 0.00 |
| 2022-02-01 | Turka Laurence A. | officer: Chief Scientific Officer | 4,921 | S-Sale | D | 2,517 | 6.57 | 16,544.24 |
| 2022-02-01 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 34,500 | A-Award | D | 34,500 | 0.00 | 0.00 |
| 2022-02-01 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 143,750 | A-Award | D | 143,750 | 6.75 | 970,312.50 |
| 2022-02-01 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 24,225 | M-Exempt | D | 8,075 | 0.00 | 0.00 |
| 2022-02-01 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 5,343 | S-Sale | D | 2,732 | 6.57 | 17,957.44 |
| 2022-01-31 | Appelhans Dannielle | officer: Chief Operating Officer | 30,000 | A-Award | A | 30,000 | 0.00 | 0.00 |
| 2022-01-31 | Appelhans Dannielle | officer: Chief Operating Officer | 125,000 | A-Award | A | 125,000 | 6.75 | 843,750.00 |
| 2022-01-31 | Carmona Jose | officer: Chief Financial Officer | 34,500 | A-Award | A | 34,500 | 0.00 | 0.00 |
| 2022-01-31 | Carmona Jose | officer: Chief Financial Officer | 143,750 | A-Award | A | 143,750 | 6.75 | 970,312.50 |
| 2022-01-29 | CAGNONI PABLO J | director, officer: CEO and President | 42,250 | M-Exempt | A | 21,250 | 0.00 | 0.00 |
| 2022-01-29 | Turka Laurence A. | officer: Chief Scientific Officer | 7,438 | M-Exempt | A | 7,438 | 0.00 | 0.00 |
| 2022-01-29 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 8,075 | M-Exempt | A | 8,075 | 0.00 | 0.00 |
| 2021-08-31 | Appelhans Dannielle | officer: Chief Operating Officer | 50,000 | A-Award | A | 50,000 | 0.00 | 0.00 |
| 2021-08-31 | Appelhans Dannielle | officer: Chief Operating Officer | 150,000 | A-Award | A | 150,000 | 21.72 | 3,258,000.00 |
| 2021-06-16 | CAGNONI PABLO J | director, officer: CEO and President | 29,320 | G-Gift | D | 2,200 | 0.00 | 0.00 |
| 2021-05-12 | Epstein David R | director | 27,919 | A-Award | A | 27,919 | 23.25 | 649,116.75 |
| 2021-05-12 | Rosenblatt Michael | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | Sohn Catherine A. | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | AFEYAN NOUBAR | director, 10 percent owner | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | Symonds Jonathan | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | Prener Anne | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | Holles Natalie C. | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-05-12 | Cuss Francis M | director | 25,000 | A-Award | A | 25,000 | 23.25 | 581,250.00 |
| 2021-04-26 | CAGNONI PABLO J | director, officer: CEO and President | 31,520 | G-Gift | D | 4,000 | 0.00 | 0.00 |
| 2021-03-19 | Flagship Ventures Fund IV General Partner LLC | director, 10 percent owner | 5,859,414 | P-Purchase | A | 70,000 | 29.00 | 2,030,000.00 |
| 2021-03-19 | Flagship Ventures Fund IV General Partner LLC | director, 10 percent owner | 2,633,703 | P-Purchase | A | 70,000 | 29.00 | 2,030,000.00 |
| 2021-03-19 | Flagship Ventures Fund IV General Partner LLC | director, 10 percent owner | 15,393,593 | P-Purchase | A | 70,000 | 29.00 | 2,030,000.00 |
| 2021-03-15 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 225,000 | M-Exempt | D | 25,000 | 7.70 | 192,500.00 |
| 2021-03-15 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 25,000 | M-Exempt | A | 25,000 | 7.70 | 192,500.00 |
| 2021-03-15 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 0 | S-Sale | D | 25,000 | 7.70 | 192,500.00 |
| 2021-02-11 | Epstein David R | director | 4,690,012 | S-Sale | D | 26,704 | 14.93 | 398,559.87 |
| 2021-02-10 | Epstein David R | director | 4,716,716 | S-Sale | D | 7,404 | 14.79 | 109,525.15 |
| 2021-02-09 | Epstein David R | director | 4,724,120 | S-Sale | D | 2,100 | 14.83 | 31,145.94 |
| 2021-02-08 | Epstein David R | director | 4,726,220 | S-Sale | D | 89,233 | 14.88 | 1,328,117.20 |
| 2021-01-29 | CAGNONI PABLO J | director, officer: CEO and President | 375,000 | A-Award | A | 375,000 | 11.97 | 4,488,750.00 |
| 2021-01-29 | CAGNONI PABLO J | director, officer: CEO and President | 85,000 | A-Award | A | 85,000 | 0.00 | 0.00 |
| 2021-01-29 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 142,500 | A-Award | A | 142,500 | 11.97 | 1,705,725.00 |
| 2021-01-29 | Coughlin Christina M. | officer: Chief Medical Officer | 142,500 | A-Award | A | 142,500 | 11.97 | 1,705,725.00 |
| 2021-01-29 | Coughlin Christina M. | officer: Chief Medical Officer | 32,300 | A-Award | A | 32,300 | 0.00 | 0.00 |
| 2021-01-29 | Turka Laurence A. | officer: Chief Scientific Officer | 131,250 | A-Award | A | 131,250 | 11.97 | 1,571,062.50 |
| 2021-01-29 | Turka Laurence A. | officer: Chief Scientific Officer | 29,750 | A-Award | A | 29,750 | 0.00 | 0.00 |
| 2021-01-29 | Keson-Brookes Maiken | officer: CLO & Corp. Secretary | 32,300 | A-Award | A | 32,300 | 0.00 | 0.00 |
| 2020-11-30 | Carmona Jose | officer: Chief Financial Officer | 400,000 | A-Award | A | 400,000 | 6.27 | 2,508,000.00 |
| 2020-05-21 | Holles Natalie C. | director | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-21 | Sohn Catherine A. | director | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-21 | AFEYAN NOUBAR | director, 10 percent owner | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-21 | Symonds Jonathan | director | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-21 | Epstein David R | director | 115,771 | A-Award | A | 115,771 | 6.22 | 720,095.62 |
| 2020-05-21 | Cuss Francis M | director | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-21 | Rosenblatt Michael | director | 25,000 | A-Award | A | 25,000 | 6.22 | 155,500.00 |
| 2020-05-15 | OH ANDREW M. | officer: Chief Financial Officer | 5,000 | M-Exempt | A | 5,000 | 4.74 | 23,700.00 |
| 2020-05-15 | OH ANDREW M. | officer: Chief Financial Officer | 755,500 | M-Exempt | D | 5,000 | 4.74 | 23,700.00 |
| 2020-04-22 | Coughlin Christina M. | officer: Chief Medical Officer | 19,000 | P-Purchase | A | 19,000 | 5.52 | 104,813.50 |
| 2020-04-14 | CAGNONI PABLO J | director, officer: CEO and President | 21,000 | P-Purchase | A | 21,000 | 4.70 | 98,693.70 |
| 2020-03-17 | Epstein David R | director | 4,815,453 | P-Purchase | A | 5,000 | 3.76 | 18,800.00 |
| 2020-03-13 | Epstein David R | director | 4,805,453 | P-Purchase | A | 5,000 | 4.00 | 20,000.00 |
| 2020-03-13 | Epstein David R | director | 4,810,453 | P-Purchase | A | 5,000 | 4.00 | 20,000.00 |
| 2020-01-31 | Coughlin Christina M. | officer: Chief Medical Officer | 375,000 | A-Award | A | 375,000 | 7.80 | 2,925,000.00 |
| 2020-01-31 | Turka Laurence A. | officer: Chief Scientific Officer | 350,000 | A-Award | A | 350,000 | 7.80 | 2,730,000.00 |
| 2020-01-31 | OH ANDREW M. | officer: Chief Financial Officer | 165,000 | A-Award | A | 165,000 | 7.80 | 1,287,000.00 |
| 2020-01-31 | CAGNONI PABLO J | director, officer: CEO and President | 500,000 | A-Award | A | 500,000 | 7.80 | 3,900,000.00 |
| 2019-12-31 | Prener Anne | director | 50,000 | A-Award | A | 50,000 | 9.50 | 475,000.00 |
| 2019-12-16 | CARPENTER CHRISTOPHER L. | officer: Chief Medical Officer | 34,843 | S-Sale | D | 48,000 | 2.87 | 137,760.00 |
| 2019-12-16 | CARPENTER CHRISTOPHER L. | officer: Chief Medical Officer | 523,157 | M-Exempt | D | 48,000 | 2.87 | 137,760.00 |
| 2019-12-16 | CARPENTER CHRISTOPHER L. | officer: Chief Medical Officer | 82,843 | M-Exempt | A | 48,000 | 2.87 | 137,760.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.